Nicholas Botwood Acquires Syndax Pharmaceuticals Shares

Nicholas Botwood, the Head of R&D and Chief Medical Officer at Syndax Pharmaceuticals, Inc., recently increased his stake in the company. On June 12, 2026, Botwood purchased 31,235 shares at an average price of $13.82 each, amounting to a total transaction value of $431,667.70. This transaction was not part of a pre-arranged trading plan, indicating a direct investment by Botwood.

Other Institutional Activity in Syndax Pharmaceuticals

Several major institutional investors have been active in Syndax Pharmaceuticals recently. BlackRock, Inc. increased its holdings by 15,424 shares, bringing its total to 8,254,426 shares valued at approximately $192.8 million. Meanwhile, Goldman Sachs Group Inc. reduced its stake by 698,588 shares, ending with 4,996,787 shares worth about $116.7 million. State Street Corp also trimmed its position by 166,476 shares, holding 4,430,076 shares valued at $103.5 million. Bank of America Corp reduced its stake by 460,910 shares, leaving it with 4,249,836 shares worth $99.3 million.

Syndax Pharmaceuticals, Inc. Stock Down 6.0%

Shares of NasdaqGS:SNDX traded around $18.26 recently. Syndax Pharmaceuticals has a market capitalization of approximately $1.62 billion. The company's stock has a 52-week low of $8.59 and a high of $25.59. It has a 50-day moving average of $20.93 and a 200-day moving average of $19.45. The stock's beta is 0.388, indicating lower volatility compared to the market. Syndax's current and quick ratios are 5.47 and 4.90, respectively, while its debt-to-equity ratio is notably high at 829.75.

Recent Earnings

Syndax Pharmaceuticals reported revenue of $217.17 million, with a modest revenue growth of 2.24%. However, the company is not yet profitable, with a net margin of -112% and a return on equity of -189.5%. The next earnings report is scheduled for August 3, 2026.

Insider Buying and Selling at Syndax Pharmaceuticals, Inc.

On June 12, 2026, Nicholas Botwood, Head of R&D and CMO at Syndax Pharmaceuticals, executed multiple transactions involving the purchase of 31,235 shares at $13.82 each. These acquisitions were not part of a Rule 10b5-1 trading plan, suggesting a personal investment decision. Previously, on June 11, 2026, Botwood also bought 22,515 shares, further increasing his stake in the company.

Analysts Set New Price Targets

Analysts have shown strong support for Syndax Pharmaceuticals, maintaining a consensus rating of "strong buy." On May 22, 2026, HC Wainwright & Co. reiterated its buy rating with a price target of $40. UBS and Barclays each maintained their buy ratings with targets of $37. Other analysts, including Goldman Sachs and Citigroup, have set price targets ranging from $34 to $57, reflecting confidence in the company's future prospects.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing cancer therapies. Headquartered in New York, the company is led by CEO Michael A. Metzger and employs about 298 people. Its key products include Revuforj, a menin inhibitor for acute leukemia, and Niktimvo, a receptor-blocking antibody for chronic graft-versus-host disease. Syndax is also working on treatments for acute myeloid leukemia and idiopathic pulmonary fibrosis.

Bottom Line

Nicholas Botwood's recent purchase of Syndax Pharmaceuticals shares highlights his confidence in the company's prospects. As insiders like Botwood continue to invest, it can be a signal of their belief in the company's future. Investors keep a close eye on these transactions and analyst ratings as indicators of potential growth. However, it's important to remember that this information is based on past filings and may not reflect current positions.